Atara Biotherapeutics (ATRA) Short Interest Ratio & Short Volume $8.02 +0.22 (+2.82%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$8.28 +0.27 (+3.30%) As of 06/18/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Atara Biotherapeutics Short Interest DataAtara Biotherapeutics (ATRA) has a short interest of 367,400 shares, representing 10.93% of the float (the number of shares available for trading by the public). This marks a -11.02% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.1, indicating that it would take 6.1 days of the average trading volume of 125,289 shares to cover all short positions.Current Short Interest367,400 sharesPrevious Short Interest412,900 sharesChange Vs. Previous Month-11.02%Dollar Volume Sold Short$2.86 millionShort Interest Ratio6.1 Days to CoverLast Record DateMay 31, 2025Outstanding Shares5,960,000 sharesFloat Size3,360,000 sharesShort Percent of Float10.93%Today's Trading Volume71,466 sharesAverage Trading Volume125,289 sharesToday's Volume Vs. Average57% Short Selling Atara Biotherapeutics? Sign up to receive the latest short interest report for Atara Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartATRA Short Interest Over TimeATRA Days to Cover Over TimeATRA Percentage of Float Shorted Over Time Atara Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/2025367,400 shares $2.86 million -11.0%10.9%6.1 $7.78 5/15/2025412,900 shares $3.14 million -20.9%12.3%6.9 $7.61 4/30/2025522,100 shares $4.17 million -21.2%13.7%8.5 $7.99 4/15/2025662,200 shares $3.96 million -0.7%17.6%6.7 $5.98 3/31/2025666,800 shares $3.96 million -7.8%17.6%3.6 $5.94 3/15/2025723,300 shares $5.24 million +1.2%19.0%3.7 $7.25 2/28/2025715,100 shares $4.94 million +6.0%18.8%3.5 $6.91 2/15/2025674,600 shares $5.79 million -4.5%18.1%3.3 $8.59 1/31/2025706,500 shares $6.27 million +29.0%18.9%3.3 $8.88 1/15/2025547,800 shares $7.21 million +2.7%12.7%2.7 $13.16 Get the Latest News and Ratings for ATRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/2024533,600 shares $7.10 million -3.3%12.4%4.8 $13.31 12/15/2024551,500 shares $5.70 million +1.4%13.0%5.4 $10.33 11/30/2024544,000 shares $6.62 million +4.7%13.0%5.1 $12.18 11/15/2024519,500 shares $6.23 million -18.4%12.4%3.5 $12.00 10/31/2024636,300 shares $5.67 million -0.5%16.0%4.6 $8.91 10/15/2024639,200 shares $5.36 million +21.4%16.1%5.4 $8.38 9/30/2024526,400 shares $4.28 million +13.7%13.3%4.5 $8.13 9/15/2024463,000 shares $4.50 million +12.8%12.6%3.6 $9.72 8/31/2024410,500 shares $3.12 million +8.5%11.0%3.2 $7.60 8/15/2024378,500 shares $2.59 million +5.0%9.4%4.7 $6.83 7/31/2024360,500 shares $3.54 million -33.2%9.0%4.5 $9.83 7/15/2024540,000 shares $6.03 million -6.1%13.4%6.7 $11.16 6/30/2024575,300 shares $4.89 million +33.5%14.4%7.6 $8.50 6/15/2024431,000 shares $5.51 million -96.2%10.8%7.2 $12.78 5/31/202411,270,000 shares $6.32 million -3.0%N/A8.5 $0.56 5/15/202411,620,000 shares $7.44 million -2.2%N/A7.2 $0.64 4/30/202411,880,000 shares $8.20 million +3.8%N/A6.9 $0.69 4/15/202411,450,000 shares $7.77 million +2.0%N/A4.4 $0.68 3/31/202411,230,000 shares $7.79 million +1.8%N/A3.7 $0.69 3/15/202411,030,000 shares $6.85 million +8.8%N/A3.2 $0.62 2/29/202410,140,000 shares $7.89 million -6.7%N/A2.8 $0.78 2/15/202410,870,000 shares $8.39 million +44.4%N/A2.9 $0.77 1/31/20247,530,000 shares $4.70 million +2.7%N/A1.3 $0.62 1/15/20247,330,000 shares $5.27 million -20.2%N/A1.4 $0.72 12/31/20239,190,000 shares $4.71 million -9.3%N/A1.9 $0.51 12/15/202310,130,000 shares $6.08 million -8.8%N/A2.2 $0.60 11/30/202311,110,000 shares $7.33 million +36.2%N/A2.8 $0.66 11/15/20238,160,000 shares $3.10 million -34.7%N/A2.2 $0.38 10/31/202312,490,000 shares $16.11 million +1.8%N/A6.1 $1.29 10/15/202312,270,000 shares $18.90 million +6.3%N/A10.5 $1.54"I'm risking my reputation on this" (Ad)Crypto book predicted the last bull run (get it FREE now) This newly updated edition contains everything we've learned from interviewing the biggest names in crypto on our Crypto 101 podcast, which has over 17 million downloads and 600+ episodes. "Crypto Revolution" isn't just another book – it's your roadmap to potentially life-changing wealth in the current crypto bull runGet Your FREE Book & Bonuses Now (First Come, First Serve) 9/30/202311,540,000 shares $17.08 million -1.1%N/A9.5 $1.48 9/15/202311,670,000 shares $17.86 million +1.2%N/A9.7 $1.53 8/31/202311,530,000 shares $16.83 million -5.4%N/A7.5 $1.46 8/15/202312,190,000 shares $22.43 million -5.9%N/A6.9 $1.84 7/31/202312,950,000 shares $28.62 million +2.6%N/A6.9 $2.21 7/15/202312,620,000 shares $23.09 million +7.9%N/A6.7 $1.83 6/30/202311,700,000 shares $18.84 million -11.4%N/A6 $1.61 6/15/202313,200,000 shares $28.25 million +4.6%N/A7 $2.14 5/31/202312,620,000 shares $19.31 million -11.0%N/A7.6 $1.53 5/15/202314,180,000 shares $31.20 million -20.3%N/A10 $2.20 4/30/202317,790,000 shares $48.21 million -7.4%N/A13.8 $2.71 4/15/202319,210,000 shares $51.67 million -3.8%N/A15.9 $2.69 3/31/202319,960,000 shares $57.88 million +19.5%N/A17.1 $2.90 3/15/202316,700,000 shares $51.44 million +18.7%N/A13.1 $3.08 2/28/202314,070,000 shares $56.98 million +0.4%N/A11.3 $4.05 2/15/202314,010,000 shares $63.47 million -1.3%N/A11.4 $4.53 1/31/202314,190,000 shares $71.94 million +4.1%N/A10.3 $5.07 1/15/202313,630,000 shares $53.02 million +4.8%N/A9.5 $3.89 12/30/202213,010,000 shares $42.67 million +5.0%N/A9.1 $3.28 12/15/202212,390,000 shares $42.87 million +1.2%N/A8.4 $3.46 11/30/202212,240,000 shares $55.45 million +1.6%N/A8.4 $4.53 11/15/202212,050,000 shares $60.37 million +1.1%N/A7.7 $5.01 10/31/202211,920,000 shares $55.55 million +0.2%N/A6.9 $4.66 10/15/202211,900,000 shares $44.39 million -3.4%N/A5.7 $3.73 9/30/202212,320,000 shares $46.57 million -0.2%N/A4.6 $3.78 9/15/202212,350,000 shares $58.05 million +10.2%N/A4.7 $4.70 8/31/202211,210,000 shares $44.95 million -0.6%N/A4.4 $4.01 8/15/202211,280,000 shares $60.24 million +7.0%N/A4.7 $5.34 7/31/202210,540,000 shares $31.94 million +31.1%N/A4.8 $3.03 7/15/20228,040,000 shares $30.95 million -24.9%N/A4.4 $3.85 6/30/202210,700,000 shares $83.35 million -5.1%N/A9.2 $7.79 6/15/202211,270,000 shares $62.55 million -3.9%N/A10.2 $5.55 5/31/202211,730,000 shares $61.00 million +6.4%N/A11 $5.20 5/15/202211,020,000 shares $0.00 -6.5%N/A9.9 $0.00 4/30/202211,790,000 shares $74.98 million +6.0%N/A11.7 $6.36 4/15/202211,120,000 shares $89.07 million +14.3%N/A11.2 $8.01 3/31/20229,730,000 shares $90.39 million +11.3%N/A9.6 $9.29 3/15/20228,740,000 shares $74.38 million +20.6%N/A9 $8.51 2/28/20227,250,000 shares $93.16 million +2.6%N/A7.7 $12.85 2/15/20227,070,000 shares $105.84 million +1.4%N/A8.6 $14.97 1/31/20226,970,000 shares $107.06 million +17.3%N/A8.1 $15.36 1/15/20225,940,000 shares $95.46 million -36.9%N/A7.1 $16.07 12/31/20219,420,000 shares $148.46 million +3.4%N/A11.3 $15.76 12/15/20219,110,000 shares $146.03 million +4.8%N/A10.7 $16.03 11/30/20218,690,000 shares $155.46 million -3.3%N/A11 $17.89 11/15/20218,990,000 shares $153.46 million -17.0%N/A10.7 $17.07 10/29/202110,830,000 shares $167.65 million -1.3%N/A13.4 $15.48 10/15/202110,970,000 shares $165.87 million -6.4%13.4%14.3 $15.12 9/30/202111,720,000 shares $209.79 million -6.1%14.4%16.4 $17.90 9/15/202112,480,000 shares $198.43 million +2.1%15.3%16.8 $15.90"I'm risking my reputation on this" (Ad)Crypto book predicted the last bull run (get it FREE now) This newly updated edition contains everything we've learned from interviewing the biggest names in crypto on our Crypto 101 podcast, which has over 17 million downloads and 600+ episodes. "Crypto Revolution" isn't just another book – it's your roadmap to potentially life-changing wealth in the current crypto bull runGet Your FREE Book & Bonuses Now (First Come, First Serve) 8/31/202112,220,000 shares $183.06 million -4.4%15.0%16.2 $14.98 8/13/202112,780,000 shares $159.11 million -2.1%15.7%17.2 $12.45 7/30/202113,060,000 shares $166.52 million +8.0%16.1%16.7 $12.75 7/15/202112,090,000 shares $165.39 million +3.7%14.9%14.4 $13.68 6/30/202111,660,000 shares $181.31 million -7.7%14.4%12.4 $15.55 6/15/202112,630,000 shares $176.82 million -0.5%15.6%14.3 $14.00 5/28/202112,690,000 shares $172.08 million -0.7%15.7%13.9 $13.56 5/14/202112,780,000 shares $188.12 million +5.3%N/A13.5 $14.72 4/30/202112,140,000 shares $176.39 million -2.9%N/A13.2 $14.53 4/15/202112,500,000 shares $173.13 million -4.7%N/A0 $13.85 3/31/202113,120,000 shares $186.57 million +12.0%N/A15.2 $14.22 3/15/202111,710,000 shares $197.90 million +5.5%N/A13 $16.90 2/26/202111,100,000 shares $184.37 million -5.5%N/A11.6 $16.61 2/12/202111,740,000 shares $225.64 million -0.7%N/A12.4 $19.22 1/29/202111,820,000 shares $224.58 million +5.0%N/A11.7 $19.00 1/15/202111,260,000 shares $212.25 million -6.1%N/A11.6 $18.85 12/31/202011,990,000 shares $246.03 million -3.8%N/A13.3 $20.52 12/15/202012,460,000 shares $292.56 million +1.0%N/A14.2 $23.48 11/30/202012,340,000 shares $287.15 million -10.1%N/A13.5 $23.27 11/15/202013,730,000 shares $247.83 million -10.3%N/A16.4 $18.05 10/30/202015,310,000 shares $206.69 million -0.8%N/A19.7 $13.50 10/15/202015,440,000 shares $214.15 million +9.0%N/A19.1 $13.87 9/30/202014,170,000 shares $183.64 million +3.3%N/A17.4 $12.96 9/15/202013,720,000 shares $214.58 million -10.1%N/A12.9 $15.64 8/31/202015,260,000 shares $205.70 million +4.5%N/A14.3 $13.48 8/14/202014,610,000 shares $177.80 million +3.5%N/A11 $12.17 7/31/202014,110,000 shares $174.82 million -4.3%N/A8.9 $12.39 7/15/202014,740,000 shares $201.05 million +8.7%N/A9.1 $13.64 6/30/202013,560,000 shares $187.67 million +15.7%N/A7.9 $13.84 ATRA Short Interest - Frequently Asked Questions What is Atara Biotherapeutics' current short interest? Short interest is the volume of Atara Biotherapeutics shares that have been sold short but have not yet been covered or closed out. As of May 31st, investors have sold 367,400 shares of ATRA short. 10.93% of Atara Biotherapeutics' shares are currently sold short. Learn More on Atara Biotherapeutics' current short interest. What is a good short interest ratio for Atara Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ATRA shares currently have a short interest ratio of 6.0. Learn More on Atara Biotherapeutics's short interest ratio. What is a good short interest percentage for Atara Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.93% of Atara Biotherapeutics' floating shares are currently sold short. Is Atara Biotherapeutics' short interest increasing or decreasing? Atara Biotherapeutics saw a decline in short interest in May. As of May 31st, there was short interest totaling 367,400 shares, a decline of 11.0% from the previous total of 412,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Atara Biotherapeutics' float size? Atara Biotherapeutics currently has issued a total of 5,960,000 shares. Some of Atara Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Atara Biotherapeutics currently has a public float of 3,360,000 shares. How does Atara Biotherapeutics' short interest compare to its competitors? 10.93% of Atara Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Atara Biotherapeutics: 4D Molecular Therapeutics, Inc. (10.15%), ProQR Therapeutics (0.78%), Bright Minds Biosciences Inc. (1.61%), CytomX Therapeutics, Inc. (26.05%), Kodiak Sciences Inc. (4.69%), Prime Medicine, Inc. (34.74%), Aerovate Therapeutics, Inc. (21.72%), AC Immune SA (2.28%), SOPHiA GENETICS SA (0.06%), Organigram Holdings Inc. (6.74%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), MicroStrategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks. What does it mean to sell short Atara Biotherapeutics stock? Short selling ATRA is an investing strategy that aims to generate trading profit from Atara Biotherapeutics as its price is falling. ATRA shares are trading up $0.22 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Atara Biotherapeutics? A short squeeze for Atara Biotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ATRA, which in turn drives the price of the stock up even further. How often is Atara Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATRA, twice per month. The most recent reporting period available is May, 31 2025. More Short Interest Resources from MarketBeat Related Companies FDMT Short Interest Data PRQR Short Interest Data DRUG Short Interest Data CTMX Short Interest Data KOD Short Interest Data PRME Short Interest Data AVTE Short Interest Data ACIU Short Interest Data SOPH Short Interest Data OGI Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ATRA) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredWar-Proof Power Why This "Weird" Government Land Auction Was No Ordinary Sale When 218,000 acres of land... smack in the m...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.